{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:44:29Z","timestamp":1785545069323,"version":"3.56.0"},"reference-count":35,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Accelerating the transition to value-based health care (VBHC) is essential to ensure sustainable care delivery. VBHC maximizes patient value by optimizing outcomes, controlling costs, and leveraging data to improve quality and patient-doctor communication. Integrating real-world data in health care is important to achieve informed decisions, especially in palliative care, where choices are complex.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study described the development and pilot-testing of an information tool that incorporates real-world outcome data for women with metastatic breast cancer who are initiating CDK4\/6 inhibitor treatment. Real-world insights are needed to better inform these patients, in particular because real-world outcomes are known to differ from trial results because of larger heterogeneity in patient characteristics, and differences in frequency of check-ups and handling side effects.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We developed an information tool together with patient representatives and clinicians using a participatory development approach that consisted of five key steps: (1) establishment of a multidisciplinary steering group (n=10 steering group members), (2) mapping of the patient journey and patients\u2019 needs through focus groups (n=9) and semistructured interviews (n=8), (3) extraction of real-world outcome data from electronic health records systems of 229 patients, (4) prototyping of the tool (n=10), and (5) pilot evaluation with the targeted patient population using semistructured interviews (n=38). We used qualitative analysis methods to analyze the focus group and interview data.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We developed a tool consisting of (1) a communication aid for use during doctor-patient consultations (ie, KIJKgesprek [Stichting Kijksluiter]) and (2) a 2-component companion app with informational videos for use at home, both incorporating real-world outcome data (ie, KIJKbericht and KIJKsluiter [Stichting Kijksluiter]). Participants valued the tool for its clarity and structured design, reporting that the outcome data reinforced their experiences and facilitated the setting of realistic expectations. However, some participants described the outcome data as overwhelming, underscoring the importance of careful framing and delivery. Preferences regarding the type, level of detail, and timing of information presentation varied among participants, highlighting the necessity of individualizing information tools to meet diverse informational needs.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Most patients valued the inclusion of real-world outcome data in the information tool, although many found it challenging to process. Preferences for the type and presentation of information varied widely among individuals. Information tools incorporating outcome data have the potential to enhance patient understanding and support informed decision-making about care that they value most. However, these tools must be designed to allow for customization, ensuring they address individual informational needs and preferences effectively.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/73156","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:52:03Z","timestamp":1785419523000},"page":"e73156-e73156","source":"Crossref","is-referenced-by-count":0,"title":["An Information Tool Incorporating Real-World Outcome Data for Women With Metastatic Breast Cancer Eligible for Treatment With a CDK4\/6 Inhibitor: Development and Evaluation"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-4972","authenticated-orcid":false,"given":"Ellen G","family":"Engelhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-6484","authenticated-orcid":false,"given":"Mariska Q N","family":"Hackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9347-1340","authenticated-orcid":false,"given":"Anne","family":"Vogelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4878-5003","authenticated-orcid":false,"given":"Afke F","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3101-3771","authenticated-orcid":false,"given":"Cristina","family":"Guerrero Paez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-0471","authenticated-orcid":false,"given":"Annette W G","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3437-3424","authenticated-orcid":false,"given":"Christa","family":"Putker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8434-0893","authenticated-orcid":false,"given":"Mariette J","family":"Agterof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-2144","authenticated-orcid":false,"given":"Ewoudt M W","family":"van de Garde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-416X","authenticated-orcid":false,"given":"Cornelia F","family":"van Uden-Kraan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"R1","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport. Integraal zorgakkoord: \u201csamen werken aan gezonde zorg\u201d. Rijksoverheid. 2022. URL: https:\/\/www.rijksoverheid.nl\/documenten\/rapporten\/2022\/09\/16\/integraal-zorgakkoord-samen-werken-aan-gezonde-zorg [Accessed 16-12-2024]"},{"issue":"3","key":"R2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/09514848211011739","article-title":"The new strategic agenda for value transformation","volume":"35","author":"van der Nat","journal-title":"Health Serv Manage Res"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2023.108043","article-title":"The use of outcome data in patient consultations from the healthcare professionals\u2019 and patients\u2019 perspectives: a mixed methods study","volume":"118","author":"Westerink","journal-title":"Patient Educ Couns"},{"issue":"8","key":"R4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055324","article-title":"Effectiveness and implementation of SHared decision-making supported by OUTcome information among patients with breast cancer, stroke and advanced kidney disease: SHOUT study protocol of multiple interrupted time series","volume":"12","author":"Hackert","journal-title":"BMJ Open"},{"issue":"2","key":"R5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jep.13321","article-title":"The use of PROMs and shared decision-making in medical encounters with patients: an opportunity to deliver value-based health care to patients","volume":"26","author":"Damman","journal-title":"J Eval Clin Pract"},{"issue":"10","key":"R6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","article-title":"Shared decision making: concepts, evidence, and practice","volume":"98","author":"Stiggelbout","journal-title":"Patient Educ Couns"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2022.09.015","article-title":"For which decisions is shared decision making considered appropriate? - a systematic review","volume":"106","author":"van der Horst","journal-title":"Patient Educ Couns"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S160462","article-title":"Palliative care: needs of advanced breast cancer patients","volume":"10","author":"Cherny","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269216310389348","article-title":"Shared decision-making in palliative care: a systematic mixed studies review using narrative synthesis","volume":"25","author":"B\u00e9langer","journal-title":"Palliat Med"},{"issue":"4","key":"R10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/02692163241238384","article-title":"Shared decision-making in palliative cancer care: a systematic review and metasynthesis","volume":"38","author":"Rabben","journal-title":"Palliat Med"},{"issue":"5","key":"R11","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00742-y","article-title":"The effect of prognostic communication on patient outcomes in palliative cancer care: a systematic review","volume":"21","author":"van der Velden","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"R12","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1634\/theoncologist.2019-0453","article-title":"Effect of a skills training for oncologists and a patient communication aid on shared decision making about palliative systemic treatment: a randomized clinical trial","volume":"25","author":"Henselmans","journal-title":"Oncologist"},{"issue":"6","key":"R13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01100-2018","article-title":"Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer","volume":"52","author":"Cramer-van der Welle","journal-title":"Eur Respir J"},{"issue":"8","key":"R14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/cncr.32697","article-title":"Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics","volume":"126","author":"Phillips","journal-title":"Cancer"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02853-0","article-title":"Development of an online patient decision aid for kidney failure treatment modality decisions","volume":"23","author":"Engels","journal-title":"BMC Nephrol"},{"key":"R16","unstructured":"Cijfers over kankerCijfers en inzichten uit de Nederlandse Kankerregistratie. Integraal kankercentrum Nederland. URL: http:\/\/www.cijfersoverkanker.nl\/ [Accessed 05-07-2026]"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis","volume":"10","author":"Benitez Fuentes","journal-title":"JAMA Oncol"},{"issue":"4","key":"R18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","journal-title":"Lancet Oncol"},{"issue":"20","key":"R19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","journal-title":"N Engl J Med"},{"issue":"10","key":"R20","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","journal-title":"Oncologist"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.23.0232","article-title":"Santeon\u2019s lessons from a decade of implementing value-based health care","volume":"5","author":"Engels","journal-title":"NEJM Catalyst"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0272989X20984134","article-title":"User involvement in the design and development of patient decision aids and other personal health tools: a systematic review","volume":"41","author":"Vaisson","journal-title":"Med Decis Making"},{"issue":"9","key":"R23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","journal-title":"Qual Health Res"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100691","article-title":"Real-world palbociclib effectiveness in patients with metastatic breast cancer: focus on neutropenia-related treatment modification strategies and clinical outcomes","volume":"35","author":"Hackert","journal-title":"Cancer Treat Res Commun"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1177\/1178223418823238","article-title":"Real-world effectiveness of palbociclib versus clinical trial results in patients with advanced\/metastatic breast cancer that progressed on previous endocrine therapy","volume":"13","author":"Bui","journal-title":"Breast Cancer (Auckl)"},{"key":"R26","unstructured":"te Paske R Vervloet M Rademakers J van Dijk L . Implementatie van Kijksluiter in de apotheek: een vragenlijstonderzoek onder apothekers. Nivel. URL: https:\/\/www.nivel.nl\/nl\/publicatie\/implementatie-van-kijksluiter-de-apotheek-een-vragenlijstonderzoek-onder-apothekers [Accessed 16-12-2025]"},{"issue":"2","key":"R27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","journal-title":"Qual Res Psychol"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Willig C Rogers WS . The SAGE Handbook of Qualitative Research in Psychology. 2017. [doi: 10.4135\/9781526405555]","DOI":"10.4135\/9781526405555"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S319239","article-title":"Treatment experiences with CDK4&6 inhibitors among women with metastatic breast cancer: a qualitative study","volume":"15","author":"Stephenson","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"R30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-022-06518-2","article-title":"Barriers and facilitators to taking CDK4\/6 inhibitors among patients with metastatic breast cancer: a qualitative study","volume":"192","author":"Conley","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"R31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11764-022-01263-3","article-title":"Mapping the experiences of people with advanced cancer across multiple cancer types-a scoping review","volume":"18","author":"Kalloger","journal-title":"J Cancer Surviv"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1933","article-title":"Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study","volume":"342","author":"Buiting","journal-title":"BMJ"},{"issue":"1","key":"R33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09911-8","article-title":"Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study","volume":"22","author":"van der Velden","journal-title":"BMC Cancer"},{"issue":"1","key":"R34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X231208448","article-title":"Potential adverse outcomes of shared decision making about palliative cancer treatment: a secondary analysis of a randomized trial","volume":"44","author":"van de Water","journal-title":"Med Decis Making"},{"issue":"10","key":"R35","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.pec.2017.05.012","article-title":"How long do I have? Observational study on communication about life expectancy with advanced cancer patients","volume":"100","author":"Henselmans","journal-title":"Patient Educ Couns"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e73156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:27:08Z","timestamp":1785536828000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e73156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2196\/73156","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"v12i3e73156"}}